Physician profile
Gregory D Sharp
NPI 1376604843
$842.54
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $320 · 2021: $12.19 · 2022: $47.98 · 2023: $82.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $389.35 | 2019-2020 | |
| Indivior INC. | $106.64 | 2019-2020 | |
| Zyla Life Sciences, INC. | $44.66 | 2019 | |
| Abbvie INC. | $42.61 | 2021-2023 | Ubrelvy |
| Kaleo, INC. | $38.81 | 2019 | |
| Orexo US, INC. | $33.81 | 2020 | |
| Idorsia Pharmaceuticals US INC | $31.24 | 2023 | Quviviq |
| Lilly USA, LLC | $30.40 | 2019 | |
| Daiichi Sankyo INC. | $22.39 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.63 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.33 | 2023 | Seglentis |
| Pfizer INC. | $16.83 | 2023 | |
| Upsher-Smith Laboratories LLC | $15.12 | 2020 | |
| Merck Sharp & Dohme LLC | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.